Bavarian terminates HPV and HBV collaboration with Janssen

A partnership concerning four diseases with Johnson & Johnson’s pharmaceutical division has been been halved, as Bavarian Nordic has halted its HPV and HBV projects.
Photo: Marcus Trappaud Bjørn/JPA
Photo: Marcus Trappaud Bjørn/JPA
by marketwire, translated by daniel pedersen

Bavarian Nordic has ended collaborations with Janssen, the pharmaceutical arm of Johnson & Johnson, in the disease areas of HPV and hepatitis B (HBV), the company reports in its first quarterly report of the year, released on Monday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading